Johan Björkegren
Principal Researcher
| Docent
E-mail: johan.bjorkegren@ki.se
Telephone: +46852482911
Visiting address: Novum, Blickagången 6, 14157 Huddinge/Stockholm
Postal address: H7 Medicin, Huddinge, H7 Metabolism/ICMC Björkegren, 171 77 Stockholm
Part of:
About me
- Focusing on cardiovascular diseases, the goal of my research is to use
multi-modal big data analysis to create reliable network models of human
biology and disease.
2013-
* PROFESSOR | Genetics and Genomic Sciences
* PROFESSOR | Medicine, Cardiology
Department of Genetics and Genomic Sciences, Icahn Institute for Genomics
and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York,
NY
2003- Associate Professor of Molecular Medicine, Karolinska Institutet,
Stockholm, Sweden
2015- Visiting Professor, University of Tartu, Tartu, Estonia
Focusing on cardiovascular diseases, the goal of my research is to use
multi-modal big data analysis to create reliable network models of human
biology and disease. Network models have enormous potential to improve our
ability to predict disease risk, identify new therapeutic targets, and to
monitor molecular effects of treatments. To achieve this goal, I have
designed and generated a range of clinical datasets of cardiovascular disease
that combine detailed clinical characteristics with imaging, genomics,
proteomics, and other types of data.
My research has long focused on cardiovascular disease. My early work
explored the role of triglyceride-rich lipoproteins in coronary artery
disease (CAD), and my postdoctoral studies in mouse models established the
hepatic gene microsomal triglyceride transfer protein as a key target to
lower plasma cholesterol levels and reduce atherosclerosis. Since then, my
primary focus has been systems analyses to generate network models from large
genomic datasets—both from CAD patients in the clinic and from cellular and
mouse models of atherosclerosis progression and regression in the laboratory.
Throughout the last decade, I have designed and led a range of clinical and
mouse model studies to elucidate the inherit complexity of CAD. As one of the
first clinical scientists to apply the emerging technologies of molecular
profiling to large patient cohorts, I have revealed the role of functionally
associated genes in several molecular networks that drive CAD. A common
complex disease such as CAD cannot be understood nor cured by targeting
isolated genes. Rather, the focus needs to be on molecular disease processes
mirrored by regulatory-gene networks that capture the combined effects of
many genetic and environmental risk factors.
To this end, at Karolinska Institutet and Tartu University Hospital, much of
my time has gone into gathering a truly unique biobank from CAD patients
undergoing different forms of heart surgery. The Stockholm-Tartu
Atherosclerosis Reverse Network Engineering Task (STARNET) is a joint study
initiative between the cardiovascular chief surgeon at the Tartu University
Hospital in Estonia, Dr. Arno Ruusalepp, and myself. Using the STARNET
bio-bank, I have since 2013 been mainly active at the Department of Genetics
and Genomic Sciences at Mount Sinai where we have generated RNA sequence data
from up to nine CAD-relevant tissues isolated from over 800 hundred
clinically well–characterized patients. This unprecedented dataset is the
main resource for our current efforts to generate network models that predict
the risk for and clinical outcomes of CAD.
My entrepreneurial ambitions have focused on translating the results of our
systems genetic research into new therapies and diagnostics for patients at
risk for or suffering CAD. I have launched several entrepreneurial projects.
Of particular importance is Clinical Gene Networks AB—the first Bio-IT
company in Sweden, founded in 2003 with the goal of exploring “clinical”
networks to generate the next generation of diagnostics and therapies based
on network models of complex diseases. Since 2019, I am reestablishing myself
at the Karolinska Institutet at the Department of Medicine at Huddinge
University Hospital.
2016 - NIH-director Francis Collins, blog on Science 2016 article [1]*
2010-2013 - Senior investigator position, Swedish Heart-Lung foundation
2008-2009 - Senior investigator award, Karolinska Institutet
2008 - Invited speaker to the Rudbeck Seminar series, Uppsala University,
Sweden
2004-2007 - Research Assistant position for the Swedish research
council
2003 - Finalist in the Young Investigator Award, International Society of
Atherosclerosis, Kyoto
1999-2002 - Fogarty fellowship (VR), University of San Francisco, University
of California
/Stockholm Business School, SU, Sweden/
*BA*
06/1988
Business
/Karolinska Institutet, Stockholm, Sweden/
*BMSc*
01/1995
/Medical School/
Karolinska University Hospital, Stockholm
*MD*
06/1998
Fully qualified physician
/Karolinska Institutet, Sweden/
*PhD*
05/1998
Lipoproteins/
Atherosclerosis
/Gladstone Institute of Cardiovascular Disease, University of California, San
Francisco, CA, USA/
*Postdoctorial*
12/2001
CAD mouse models
[1] https://directorsblog.nih.gov/2016/09/08/cardiometabolic-disease-big-data-tackles-a-big-health-problem/
Research
- I use multi-modal big data analysis to create new and reliable network models
of human molecular biology in health and disease that can lead to better
disease prediction, monitoring and therapies. To this effort I have created
clinical datasets of mainly cardiovascular disease patients in Sweden,
Estonia and now in the US that are enriched for many of these data modalities
including genetics, -omics (epigenetics, RNA, proteins, metabolites and
lipids) combined with detailed clinical characteristics including imaging.
I have a broad background in the design and analysis of clinical studies
apprehending and applying the new screening and bioinformatics analysis tools
to elucidate the true complexity of common diseases. The focus of these
studies has been the role of functionally associated genes in molecular
networks driving disease. Vital to this approach of a more granular
understanding of complex disease biology is to originate these studies in
humans suffering the disease whereas animal and cell disease model systems
have chiefly been used for the purpose of validating key disease drivers and
processes first identified in humans (i.e. top-down vs. a bottom-up
approach).
*STARNET bio-bank*
This effort has now resulted in one of the world’s most unique
cardiometabolic disease (CMD)-related dataset, STARNET, published in /Science
and Nature /journals/. /Currently, we are expanding STARNET (v2) (with 1316
coronary artery disease (CAD)-affected subjects and 372 subjects verified to
be CAD-free (nonCAD)) now processing samples allowing transomic analyses
(epigenomics, transcriptomics and proteomics) including single nuclei RNAseq
and with the additions of portal vein and the gut microbiome.* *Moving
forward, I am highly driven, motivated and focused to expand the central
theme of my research strategies - /a global understanding of the molecular
regulatory-gene landscape enabling diagnostics and therapies of
molecularly-defined subcategories of CMD patients (i.e. precision medicine)/.
*Complete List of Published Work in MyBibliography:*
https://www.ncbi.nlm.nih.gov/myncbi/johan.bjorkegren.1/bibliography/public/
[1]
1) Franzén et al. *“*Cardiometabolic Risk Loci Share Downstream /Cis/ and
/Trans/ Genes Across Tissues and Diseases” /Science /19 Aug 2016:Vol.
353, Issue 6301, pp. 827-830.
2) Zeng et al.. “Contribution of Gene Regulatory Networks to Heritability
of Coronary Artery Disease”./ J Am Coll Cardiol. /2019 Jun
18 - 73(23):2946-2957. doi: 10.1016/j.jacc.2019.03.520.
3) *Cohain el al. “*/An integrative multiomic network model links lipid
metabolism to glucose regulation in coronary artery disease/” Nat
Commun. 2021 Jan 22 - 12(1):547.
4) *Hartman et al. “*/Sex-stratified gene regulatory networks reveal
differentially activated key drivers of human coronary artery disease”/
Circulation. 2021 Feb 16 - 143(7):713-726.
5) Koplev et al. “/A mechanistic framework for cardiometabolic and
coronary artery diseases/” Nature Cardiovascular Research, in press
(available online January 12th, 2022)
*Historical contributions to Science:*
*1. *In my PhD work I studied the role of apolipoprotein (apo) and lipid
composition of triglyceride-rich lipoproteins (TRLs) for CAD. I found that
the TRL content of apoCI was particularly relevant for risk of developing
early CAD. This work involved both sampling and characterization of patients
and a wide range of molecular laboratory methods.
1) 1) Bjorkegren, J. (2006). "Dual roles of apolipoprotein CI in the
formation of atherogenic remnants." /Curr Atheroscler Rep/ 8(1): 1-2.
2) Hamsten, A., A. Silveira, S. Boquist, R. Tang, M. G. Bond, U. de
Faire and J. Bjorkegren (2005). "The apolipoprotein CI content of
triglyceride-rich lipoproteins independently predicts early
atherosclerosis in healthy middle-aged men." J Am Coll Cardiol 45(7):
1013-1017
3) Bjorkegren, J., S. Boquist, A. Samnegard, P. Lundman, P. Tornvall, C.
G. Ericsson and A. Hamsten (2000). "Accumulation of apolipoprotein
C-I-rich and cholesterol-rich VLDL remnants during exaggerated
postprandial triglyceridemia in normolipidemic patients with coronary
artery disease." /Circulation/ 101(3):227-230.
4) Bjorkegren, J., F. Karpe, R. W. Milne and A. Hamsten (1998).
"Differences in apolipoprotein and lipid composition between human
chylomicron remnants and very low-density lipoproteins isolated from
fasting and postprandial plasma." /J Lipid Res/ 39(7): 1412-1420.
2) During my post-doc years at UCSF, CA, I generated genetically modified
mouse models relevant for CAD and atherosclerosis. I carefully
investigated the hepatic gene microsomal triglyceride transfer protein
(/Mttp/) conditional gene knockout in the liver and heart examining the
effects of /Mttp /deletion on plasma cholesterol levels, liver steatosis
and fat accumulation and secretion of lipoproteins from the heart.
1) Larsson, S. L., J. Skogsberg and J. Bjorkegren (2004). "The
low-density lipoprotein receptor prevents secretion of dense
apoB100-containing lipoproteins from the liver." /J Biol Chem
/279(2): 831-836.
2) Bjorkegren, J., A. Beigneux, M. O. Bergo, J. J. Maher and S. G. Young
(2002). "Blocking the secretion of hepatic very low-density
lipoproteins renders the liver more susceptible to toxin-induced
injury." /J Biol Chem/ 277(7): 5476-5483.
3) Bjorkegren et al. (2001). "Lipoprotein secretion and triglyceride
stores in the heart." /J Biol Chem/ 276(42): 38511-38517
4) Raabe et al. (1999). "Analysis of the role of microsomal triglyceride
transfer protein in the liver of tissue-specific knockout mice." /J
Clin Invest/ 103(9): 1287-1298.
3) I have extensively used these mouse models also after my post-doc for
key CAD target validation and in combination with holistic functional
transcriptomic studies of gene expression during atherosclerosis
progression and regression. From these studies, I have defined regulatory
gene networks driving atherosclerosis progression and regression that are
highly relevant for my current studies of patients of CAD to establish
networks active both in early and late phases of coronary
atherosclerosis.
1) Bjorkegren, J. et al. (2014). "Plasma cholesterol-induced lesion
networks activated before regression of early, mature, and advanced
atherosclerosis." /PLoS Genet./ 10(2): e1004201.
2) Shang et al. (2014). "Lim domain binding 2: a key driver of
transendothelial migration of leukocytes and atherosclerosis."
/Arterioscler Thromb Vasc Biol/ 34(9): 2068-2077.
3) Skogsberg et al. (2008). "Transcriptional profiling uncovers a
network of cholesterol-responsive atherosclerosis target genes."
/PLoS. Genet./ 4(3): e1000036.
4) Kovacs et al. (2007). "Human C-reactive protein slows atherosclerosis
development in a mouse model with human-like hypercholesterolemia."
/Proc. Natl. Acad. Sci./ U S A 104(34): 13768-13773.
4) I have uniquely designed clinical studies to sample multiple vascular and
metabolic tissues enabling systems genetics approaches to study CAD by
generating genomics datasets from the STAGE and STARNET cohorts. For
these types of functional genomics studies, I have evolved as a leader in
the field of network CAD biology.
1) Foroughi et al. (2015). "Expression quantitative trait Loci acting
across multiple tissues are enriched in inherited risk for coronary
artery disease." /Circ Cardiovasc Genet/ 8(2): 305-315.
2) Schadt, E. E. and J. L. Bjorkegren (2012). "NEW: network-enabled
wisdom in biology, medicine, and health care." /Science Transl. Med/.
4(115): 115rv111
3) Hägg et al. (2009). "Multi-organ expression profiling uncovers a
gene module in coronary artery disease involving transendothelial
migration of leukocytes and LIM domain binding 2: the Stockholm
Atherosclerosis Gene Expression (STAGE) study." /PLoS genetics/ 5:
e1000754.
4) Tegner, J. and J. Bjorkegren (2007). "Perturbations to uncover gene
networks." /Trends Genet/ 23(1): 34-41.
5) Founder of one of Sweden’s leading biotech companies in the Bio-IT
sectors (Clinical Gene Networks AB). www.clinicalgenenetworks.com [2]* *
[1] https://www.ncbi.nlm.nih.gov/myncbi/johan.bjorkegren.1/bibliography/public/
[2] http://www.clinicalgenenetworks.com
Teaching
- *TEACHING/LECTURING AT THE KAROLINSKA INSTITUTET, 2002–2013*
*Lecturer in the PhD program*, “Systems biology- from model organism to
complex diseases” (# 2085) at the School of Medical Bioinformatics (FMB),
Strategy and Development Office, Karolinska Institutet: Cardiovascular
systems medicine”, 2 scheduled hours per semester, 2006-2012
*Lecturer in the PhD program*, “Bioinformatics in Medicine” The School of
Medical Bioinformatics, Center for Medical Innovation: 1 scheduled hour per
semester, 2002-2005.
*Lecturer at the PhD program*, “An overview of the process of
atherosclerosis” (# 1551) at the Karolinska University Hospital, Solna 1
scheduled hour per year. “Systems biological approach to
atherosclerosis”, 2005–2009.
*Lecturer in the PhD program of Clinical Sciences at the Karolinska
University Hospital, Huddinge*: “From gene to disease”. Atherosclerosis:
Gen-protein function. 1 scheduled hour per semester, 2003–2005.
*Lecturer in the Biomedical School, semester 6, “Molecular Medicine”, the
Karolinska University Hospital, Solna:* 1 scheduled hour per semester,
2002–2004.
*“Your food intake is a matter of your heart”, Health care* at Karolinska
Institutet, 2004, 2005, 2008.
Articles
-
Article: CIRCULATION RESEARCH. 2023;132(9):1144-1161
-
Article: CIRCULATION RESEARCH. 2023;132(3):323-338
-
Article: ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY. 2023;249:114426
-
Article: NATURE GENETICS. 2022;54(12):1803-1815
-
Article: JOURNAL OF AGING STUDIES. 2022;63:101074
-
Article: DEVELOPMENTAL CELL. 2022;57(20):2426-2443.e6
-
Article: CARDIOVASCULAR RESEARCH. 2022;118(13):2792-2804
-
Article: METABOLITES. 2022;12(9):840
-
Article: PLOS GENETICS. 2022;18(6):e1010261
-
Article: NATURE GENETICS. 2022;54(6):804-816
-
Article: STEM CELL REPORTS. 2022;17(5):1089-1104
-
Article: CARDIOVASCULAR RESEARCH. 2022;118(4):1088-1102
-
Article: BASIC RESEARCH IN CARDIOLOGY. 2022;117(1):6
-
Article: CIRCULATION-GENOMIC AND PRECISION MEDICINE. 2022;15(1):e003365
-
Article: NAT CARDIOVASC RES. 2022;1(1):85-100
-
Article: NATURE METABOLISM. 2021;3(11):1552-1568
-
Article: JOURNAL OF CLINICAL INVESTIGATION. 2021;131(15):131178
-
Article: JOURNAL OF HUMAN GENETICS. 2021;66(6):625-636
-
Article: CIRCULATION. 2021;143(18):1809-1823
-
Article: NATURE COMMUNICATIONS. 2021;12(1):1610
-
Article: EUROPEAN HEART JOURNAL. 2021;42(9):919-933
-
Article: CIRCULATION. 2021;143(7):713-726
-
Article: NATURE COMMUNICATIONS. 2021;12(1):547
-
Article: CIRCULATION RESEARCH. 2020;127(12):1552-1565
-
Article: CIRCULATION. 2020;142(21):2045-2059
-
Article: BASIC RESEARCH IN CARDIOLOGY. 2020;115(6):67
-
Article: ATHEROSCLEROSIS. 2020;311:20-29
-
Article: NATURE COMMUNICATIONS. 2020;11(1):3953
-
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(27):15818-15826
-
Article: BIOINFORMATICS. 2020;36(12):3910-3912
-
Article: BIOINFORMATICS. 2020;36(6):1807-1813
-
Article: CARDIOVASCULAR RESEARCH. 2020;116(1):63-77
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2019;39(11):2386-2401
-
Article: NATURE MEDICINE. 2019;25(10):1576-1588
-
Article: NATURE COMMUNICATIONS. 2019;10(1):3834
-
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2019;73(23):2946-2957
-
Article: CIRCULATION-GENOMIC AND PRECISION MEDICINE. 2019;12(6):e002390
-
Article: NUCLEIC ACIDS RESEARCH. 2019;47(7):e39
-
Article: NATURE GENETICS. 2019;51(4):592-599
-
Article: DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION. 2019;2019:baz046
-
Article: NATURE COMMUNICATIONS. 2018;9(1):5141
-
Article: PLOS GENETICS. 2018;14(12):e1007799
-
Article: PLOS GENETICS. 2018;14(11):e1007755
-
Article: CIRCULATION-GENOMIC AND PRECISION MEDICINE. 2018;11(9):e002030
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2018;38(8):1711-1722
-
Article: STEM CELL REPORTS. 2018;11(1):242-257
-
Article: JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY. 2018;119:147-154
-
Article: CELL METABOLISM. 2018;27(5):1138-1155.e6
-
Article: NATURE GENETICS. 2018;50(4):524-537
-
Article: SCIENTIFIC REPORTS. 2018;8(1):3434
-
Article: PEERJ. 2018;6:e4466
-
Article: ATHEROSCLEROSIS. 2017;267:39-48
-
Article: SCIENTIFIC REPORTS. 2017;7(1):10633
-
Article: NATURE GENETICS. 2017;49(9):1385-1391
-
Article: CIRCULATION. 2017;136(5):476-489
-
Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2017;100(6):885-894
-
Article: AMERICAN HEART JOURNAL. 2017;187:170-181
-
Article: CIRCULATION-GENOMIC AND PRECISION MEDICINE. 2017;10(2):e001664
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2017;37(3):534-542
-
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2017;69(7):823-836
-
Article: CIRCULATION RESEARCH. 2017;120(2):341-353
-
Article: GENOME BIOLOGY. 2016;17(1):247
-
Article: G3-GENES GENOMES GENETICS. 2016;6(10):3361-3371
-
Article: SCIENCE. 2016;353(6301):827-830
-
Article: NATURE COMMUNICATIONS. 2016;7:12092
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2016;36(6):1240-1246
-
Article: CELL SYSTEMS. 2016;2(3):196-208
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2015;35(10):2207-2217
-
Article: ATHEROSCLEROSIS. 2015;239(2):528-538
-
Article: CIRCULATION-GENOMIC AND PRECISION MEDICINE. 2015;8(2):305-315
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2014;34(9):2068-2077
-
Article: PLOS GENETICS. 2014;10(2):e1004201
-
Article: BMC BIOINFORMATICS. 2014;15:11
-
Article: CELL CYCLE. 2014;13(23):3645-3658
-
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2011;28(2):247-253
-
Article: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2011;27(6):851-857
-
Article: PLOS ONE. 2011;6(4):e18248
-
Article: METABOLISM-CLINICAL AND EXPERIMENTAL. 2011;60(1):114-120
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2010;30(5):962-967
-
Article: IET SYSTEMS BIOLOGY. 2009;3(4):219-228
-
Article: NATURE GENETICS. 2009;41(5):553-562
-
Article: IET SYSTEMS BIOLOGY. 2009;3(2):113-123
-
Article: BMC BIOINFORMATICS. 2009;10:38
-
Article: JOURNAL OF MACHINE LEARNING RESEARCH. 2009;10:1071-1094
-
Article: BIOINFORMATICS AND BIOLOGY INSIGHTS. 2008;2:307-316
-
Article: LIPIDS. 2008;43(7):673-679
-
Article: LIPIDS. 2008;43(4):353-360
-
Article: PLOS GENETICS. 2008;4(3):e1000036
-
Article: ATHEROSCLEROSIS. 2008;196(2):514-522
-
Article: PLOS ONE. 2008;3(11):e3771
-
Article: CLINICAL ENDOCRINOLOGY. 2008;68(1):51-58
-
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(34):13768-13773
-
Article: BMC BIOINFORMATICS. 2007;8:150
-
Article: JOURNAL OF MACHINE LEARNING RESEARCH. 2007;8:589-612
-
Article: GENOMICS. 2006;88(2):133-142
-
Article: PLOS GENETICS. 2006;2(5):755-761
-
Article: BMC BIOINFORMATICS. 2006;7:51
-
Article: CURRENT ATHEROSCLEROSIS REPORTS. 2006;8(1):1-2
-
Article: PATTERN RECOGNITION LETTERS. 2005;26(14):2295-2308
-
Article: CLINICAL CHEMISTRY. 2005;51(5):911-913
-
Article: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2005;45(7):1013-1017
-
Article: EUROPEAN JOURNAL OF HUMAN GENETICS. 2004;12(9):770-774
-
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(2):831-836
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2002;22(9):1470-1474
-
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2002;277(7):5476-5483
-
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(42):38511-38517
-
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2000;275(11):7515-7520
-
Article: CIRCULATION. 1999;100(7):723-728
-
Article: JOURNAL OF CLINICAL INVESTIGATION. 1999;103(9):1287-1298
-
Article: JOURNAL OF LIPID RESEARCH. 1998;39(7):1412-1420
-
Article: JOURNAL OF LIPID RESEARCH. 1998;39(2):423-436
-
Article: JOURNAL OF LIPID RESEARCH. 1997;38(2):301-314
-
Article: JOURNAL OF LIPID RESEARCH. 1996;37(1):76-86
-
Article: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 1995;15(2):199-207
- Show more
All other publications
-
Corrigendum: NATURE GENETICS. 2022;54(8):1259
-
Review: CELL. 2022;185(10):1630-1645
-
Corrigendum: BASIC RESEARCH IN CARDIOLOGY. 2022;117(1):19
-
Review: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2021;77(20):2531-2550
-
Meeting abstract: FASEB JOURNAL. 2021;35
-
Corrigendum: NATURE COMMUNICATIONS. 2020;11(1):4493
-
Corrigendum: BMC MEDICAL GENOMICS. 2019;12(1):154
-
Published paper: BMC MEDICAL GENOMICS. 2019;12(Suppl 6):108
-
Corrigendum: NATURE GENETICS. 2019;51(7):1192-1193
-
Meeting abstract: BIOLOGICAL PSYCHIATRY. 2019;85(10):S98
-
Review: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2018;72(18):2181-2197
-
Meeting abstract: HEART. 2018;104:A71
-
Review: NATURE REVIEWS CARDIOLOGY. 2018;15(1):9-19
-
Review: JACC-BASIC TO TRANSLATIONAL SCIENCE. 2017;2(3):311-327
-
Editorial comment: CELL SYSTEMS. 2017;4(1):7-15
-
Review: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2016;67(14):1725-1737
-
Review: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2015;65(8):830-845
-
Review: SCIENCE TRANSLATIONAL MEDICINE. 2012;4(115):115rv1
-
Editorial comment: GENOME MEDICINE. 2012;4(3):29
-
Published paper: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. 2009;1158:265-275
-
Review: LAKARTIDNINGEN. 2007;104(42):3042-3045
-
Published paper: INTERNATIONAL JOURNAL OF APPROXIMATE REASONING. 2007;45(2):211-232
-
Review: JOURNAL OF LIPID RESEARCH. 2007;48(2):267-277
-
Review: TRENDS IN GENETICS. 2007;23(1):34-41
-
Published paper: CELLULAR IMMUNOLOGY. 2006;244(2):105-109
-
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):497-498
-
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):357
-
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):200-201
-
Published paper: LECTURE NOTES IN COMPUTER SCIENCE. 2006;4212:719-726
-
Published paper: BIOINFORMATICS. 2005;21 Suppl 2:ii224-ii229
-
Published paper: LECTURE NOTES IN COMPUTER SCIENCE. 2005;3571:136-147
-
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2003;4(2):232
-
Meeting abstract: ATHEROSCLEROSIS. 1999;144:124
-
Meeting abstract: ATHEROSCLEROSIS. 1997;134(1-2):286
-
Meeting abstract: ATHEROSCLEROSIS. 1997;134(1-2):337
- Show more
Employments
- Principal Researcher, Department of Medicine, Huddinge, Karolinska Institutet, 2022-
Degrees and Education
- Docent, Karolinska Institutet, 2003
- University Medical Degree, Karolinska Institutet, 1995